JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

146.74

-0.99%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

110.09 -0.09

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

108.91

Максимум

111.33

Ключови измерители
By Trading Economics
Приходи	2.9M -47M
Продажби	16M 49M
Марж на печалбата	-96.144
Служители	283
EBITDA	6.9M -40M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+8.63% upside

Дивиденти
By Dow Jones
Следващи печалби	4.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.5B 7.5B
Предишно отваряне	110.18
Предишно затваряне	110.09

Настроения в новините

By Acuity

50%

148 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

26.10.2025 г., 23:52 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

26.10.2025 г., 23:52 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen -- Market Talk

26.10.2025 г., 23:46 ч. UTC

Пазарно говорене

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26.10.2025 г., 23:41 ч. UTC

Пазарно говорене

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26.10.2025 г., 23:34 ч. UTC

Печалби

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26.10.2025 г., 23:32 ч. UTC

Печалби

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26.10.2025 г., 23:30 ч. UTC

Печалби

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26.10.2025 г., 22:29 ч. UTC

Печалби

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26.10.2025 г., 22:29 ч. UTC

Печалби

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26.10.2025 г., 22:29 ч. UTC

Печалби

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26.10.2025 г., 22:29 ч. UTC

Печалби

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26.10.2025 г., 22:16 ч. UTC

Печалби

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26.10.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26.10.2025 г., 19:29 ч. UTC

Придобивния, сливания и поглъщания

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26.10.2025 г., 06:39 ч. UTC

Печалби

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26.10.2025 г., 06:39 ч. UTC

Печалби

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26.10.2025 г., 06:39 ч. UTC

Печалби

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

24.10.2025 г., 21:24 ч. UTC

Пазарно говорене

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24.10.2025 г., 21:07 ч. UTC

Печалби

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24.10.2025 г., 20:58 ч. UTC

Печалби

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

24.10.2025 г., 20:40 ч. UTC

Печалби

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24.10.2025 г., 20:24 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:23 ч. UTC

Печалби

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24.10.2025 г., 20:13 ч. UTC

Печалби

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24.10.2025 г., 20:07 ч. UTC

Пазарно говорене

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24.10.2025 г., 19:40 ч. UTC

Пазарно говорене

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24.10.2025 г., 19:35 ч. UTC

Пазарно говорене

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24.10.2025 г., 19:33 ч. UTC

Печалби

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

8.63% нагоре

12-месечна прогноза

Среден 120 USD 8.63%

Висок 142 USD

Нисък 95 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

148 / 373 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.